基因治療合作與授權協議：2016-2025

本報告全面深入分析了全球領先的生物製藥公司簽署的基因治療協議，並提供前所未有的資訊取得管道。

本報告詳細闡述並分析了公司簽署基因治療協議的原因和方法。這些協議通常包含多個組成部分，從合作研發開始，最終實現成果的商業化。

本報告涵蓋合作、開發、研究和授權協議。

本報告包​​含自2016年以來公佈的787項基因治療交易的完整清單，其中包括可用的財務條款以及各方披露的實際基因治療合作交易的在線記錄鏈接。此外，在條件允許的情況下，記錄中還包括公司及其合作夥伴向美國證券交易委員會提交的合約文件。

主要優勢：

• 了解自 2016 年以來的合約趨勢
• 查看基因治療領域的合作與授權協議
• 基準分析：確定交易市場價值
• 財務條款：預付款、里程碑付款、特許權使用費
• 依公司名稱（A-Z）、合約類型和治療領域分類的合約目錄
• 以價值排名的主要交易
• 最活躍的交易撮合者
• 識別每份合約的資產詳情和條款
• 存取合約文件：深入了解合約結構
• 盡職調查：評估擬議合約條款是否適合您的合作夥伴
• 節省數百小時的研究時間

分析合約內容有助於進行以下方面的盡職調查：

• 合約授予或選擇哪些具體權利？
• 合約實際授予合作夥伴哪些權利？
• 授予哪些獨家銷售權？
• 合約的付款結構是什麼？
• 銷售和付款將如何審計？
• 合約期限是多久？
• 合約的關鍵條款是如何定義的？
• 智慧財產權（IPR）將如何處理，所有權歸誰？
• 誰負責商業化？
• 誰負責開發、供應和生產？
• 如何管理保密性和資訊揭露？
• 如何解決爭議？
• 合約在什麼情況下可以終止？
• 如果所有權發生變更，會發生什麼事？
• 雙方約定的轉授權和分包條款是什麼？
• 公司通常會包含哪些標準條款？
• 哪些標準條款會因交易對手和合約類型而異？
• 根據合約法，該公司要求適用哪一方（法院）的管轄法律？

目錄

摘要整理

第一章：引言

第二章：基因治療合約趨勢

• 過去幾年基因治療合約數量
• 最活躍的承包商
• 依合約類型劃分的基因治療合約
• 依治療領域劃分的基因治療合約
• 依行業劃分的基因治療合約
• 基因治療合約條款

第三章：主要基因治療合約

• 以合約金額劃分的主要基因治療合約

第四章：最活躍的基因治療承包商

• 最活躍的基因治療承包商
• 承包商簡介最活躍的基因治療承包商

第五章：基因治療合約交易目錄

• 基因治療合約交易目錄

第六章：依技術類型劃分的基因治療合約

• 合約目錄
• 依公司（A-Z）劃分的合約目錄
• 依合約類型劃分的合約目錄
• 依治療領域劃分的合約目錄
• 合約類型定義
• 關於 Biopharma Research Ltd
• 當前合作夥伴
• 當前協議
• 來自目前合作夥伴的最新報告標題

Gene Therapy Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the gene therapy deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of gene therapy deals from 2016 to 2025.

The report provides a detailed understanding and analysis of how and why companies enter gene therapy deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 787 gene therapy deals announced since 2016 including financial terms where available including links to online deal records of actual gene therapy partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of gene therapy dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in gene therapy dealmaking since 2016.

Chapter 3 provides an overview of the leading gene therapy deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in gene therapy dealmaking with a brief summary followed by a comprehensive listing of gene therapy deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of gene therapy deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of gene therapy partnering deals signed and announced since Jan 2016. The chapter is organized by specific gene therapy technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in gene therapy deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Gene Therapy Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse gene therapy collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Gene Therapy Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of gene therapy trends and structure of deals entered into by leading biopharma companies worldwide.

Gene Therapy Collaboration and Licensing Deals includes:

• Trends in gene therapy dealmaking in the biopharma industry
• Directory of gene therapy deal records covering pharmaceutical and biotechnology
• The leading gene therapy deals by value
• Most active gene therapy licensing dealmakers
• Gene Therapy Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in gene therapy dealmaking

• 2.1. Introduction
• 2.2. Gene therapy deals over the years
• 2.3. Most active gene therapy dealmakers
• 2.4. Gene therapy deals by deal type
• 2.5. Gene therapy deals by therapy area
• 2.6. Gene therapy deals by industry sector
• 2.7. Deal terms for gene therapy deals
  • 2.7.1 Gene therapy deals headline values
  • 2.7.2 Gene therapy deal upfront payments
  • 2.7.3 Gene therapy deal milestone payments
  • 2.7.4 Gene therapy royalty rates

Chapter 3 - Leading gene therapy deals

• 3.1. Introduction
• 3.2. Top gene therapy deals by value

Chapter 4 - Most active gene therapy dealmakers

• 4.1. Introduction
• 4.2. Most active gene therapy dealmakers
• 4.3. Most active gene therapy deals company profiles

Chapter 5 - Gene therapy contracts dealmaking directory

• 5.1. Introduction
• 5.2. Gene therapy contracts dealmaking directory

Chapter 6 - Gene therapy dealmaking by technology type

• Deal directory
• Deal directory - Gene therapy deals by company A-Z
• Deal directory - Gene therapy deals by deal type
• Deal directory - Gene therapy deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Gene therapy deals since 2016
• Figure 2: Active gene therapy dealmaking activity - 2016 - 2025
• Figure 3: Gene therapy deals by deal type since 2016
• Figure 4: Gene therapy deals by therapy area since 2016
• Figure 5: Gene therapy deals by industry sector since 2016
• Figure 6: Gene therapy deals with a headline value
• Figure 7: Gene therapy deals with an upfront value
• Figure 8: Gene therapy deals with a milestone value
• Figure 9: Gene therapy deals with a royalty rate value
• Figure 10: Top gene therapy deals by value since 2016
• Figure 11: Most active gene therapy dealmakers 2016 - 2025
• Figure 12: Gene therapy deals by technology type since 2016